Patents by Inventor Jennifer Van Eyk
Jennifer Van Eyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11193947Abstract: Described herein are methods for assessing the risk of cardiovascular disease in a subject in need thereof by detecting the presence of one or more cleavage products of the one or more natriuretic peptides over a period of time, wherein the presence of one or more cleavage products is indicative of an increased risk of the subject developing cardiovascular disease. Provided herein are compositions and kits comprising a non-natural natriuretic peptide comprising one or more D-amino acids. Also provided herein are methods of diagnosing a subject for a disease and treating the subject for the disease, wherein the method comprises the use of a non-natural natriuretic peptide comprising one or more D-amino acids.Type: GrantFiled: October 4, 2018Date of Patent: December 7, 2021Assignee: CEDARS-SINAI MEDICAL CENTERInventors: Shenyan Zhang, Koen Raedschelders, Jennifer Van Eyk
-
Publication number: 20210302441Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.Type: ApplicationFiled: April 7, 2021Publication date: September 30, 2021Inventors: Jennifer Van Eyk, Beth McQuiston, Saul Datwyler, Raj Chandran, Vidya Venkatraman, Shenyan Zhang
-
Patent number: 11105817Abstract: Provided herein are methods and markers for diagnosing cardiovascular disease and/or neurodegenearative diseases in a subject. The methods include obtaining a biological sample from a subject in need of diagnosis and detecting the amount of a citrullinated protein or a citrullinated peptide in the biological sample obtained from said subject.Type: GrantFiled: June 20, 2016Date of Patent: August 31, 2021Assignee: Cedars-Sinai Medical CenterInventors: Jennifer Van Eyk, Justyna Fert-Bober, Erin Crowgey, Ronald Holewinski, Benjamin Phillip Berman
-
Publication number: 20210025902Abstract: Described herein are methods for determining the status of Urologic Chronic Pelvic Pain Syndrome (UCPPS) in a subject and/or treating urologic chronic pelvic pain syndrome (UCPPS).Type: ApplicationFiled: February 26, 2019Publication date: January 28, 2021Applicant: Cedars-Sinai Medical CenterInventors: Jennifer ANGER, Anne Lenore ACKERMAN, Jennifer VAN EYK, Qin FU, Weston SPIVIA
-
Publication number: 20200292558Abstract: Described herein are methods for identification/discovery of protein biomarkers for chronic kidney disease (CKD) and diagnosing and/or prognosing and/or predicting progression of and/or treating chronic kidney disease (CKD).Type: ApplicationFiled: October 12, 2018Publication date: September 17, 2020Applicants: Cedars-Sinai Medical Center, THE JOHNS HOPKINS UNIVERSITYInventors: Jennifer VAN EYK, Qin FU, Vidya VENKATRAMAN, Zongming FU, Josef CORESH
-
Publication number: 20200217854Abstract: Provided herein are methods, kits, and assays for identifying and quantifying a mitochondrial protein in a sample using mass spectrometry. Also provided herein are methods, kits, and assays for determining a mitochondrial protein biomarker signature for a subject using mass spectrometry.Type: ApplicationFiled: September 25, 2018Publication date: July 9, 2020Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Sarah Parker, Aleksandr Stotland, Roberta Gottlieb, Jennifer Van Eyk, Weston Spivia
-
Publication number: 20190383832Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.Type: ApplicationFiled: December 27, 2018Publication date: December 19, 2019Inventors: Jennifer Van Eyk, Beth McQuiston, Saul Datwyler, Raj Chandran, Vidya Venkatraman, Shenyan Zhang
-
Publication number: 20190369114Abstract: Sample preparation for proteomic analysis of complex biological samples by mass spectrometry is a tedious and time-consuming process with many steps where technical variations can be introduced and propagated. We describe an automated trypsin digestion workflow that yields uniformly-processed samples in less than 5 hours. Reproducible quantitation of hundreds of peptides from numerous proteins was seen across replicates, days, instruments, and laboratory sites, demonstrating the broad applicability of this approach.Type: ApplicationFiled: July 18, 2019Publication date: December 5, 2019Applicant: Cedars-Sinai Medical CenterInventors: Jennifer VAN EYK, Qin FU, Vidya VENKATRAMAN, Irina TCHERNYSHYOV
-
Patent number: 10352942Abstract: Described herein are methods for identifying signature peptides for quantifying a polypeptide of interest in a sample. The methods include cleaving the polypeptide into peptides; detecting a multiplicity of the peptides with a quantitative analytical instrument; comparing the linearity of signals attributable to pairs of the peptides in a multiplicity of samples; and selecting signature peptides from a group of peptides with more highly correlated signals.Type: GrantFiled: May 31, 2016Date of Patent: July 16, 2019Assignees: Cedars-Sinai Medical Center, The Johns Hopkins UniversityInventors: Eric Grote, Qin Fu, Jennifer Van Eyk, Vidya Venkatraman
-
Publication number: 20190025333Abstract: Described herein are methods for assessing the risk of cardiovascular disease in a subject in need thereof by detecting the presence of one or more cleavage products of the one or more natriuretic peptides over a period of time, wherein the presence of one or more cleavage products is indicative of an increased risk of the subject developing cardiovascular disease. Provided herein are compositions and kits comprising a non-natural natriuretic peptide comprising one or more D-amino acids. Also provided herein are methods of diagnosing a subject for a disease and treating the subject for the disease, wherein the method comprises the use of a non-natural natriuretic peptide comprising one or more D-amino acids.Type: ApplicationFiled: October 4, 2018Publication date: January 24, 2019Applicant: Cedars-Sinai Medical CenterInventors: Shenyan ZHANG, Koen RAEDSCHELDERS, Jennifer VAN EYK
-
Publication number: 20180299467Abstract: Provided herein are methods and markers for diagnosing cardiovascular disease and/or neurodegenearative diseases in a subject. The methods include obtaining a biological sample from a subject in need of diagnosis and detecting the amount of a citrullinated protein or a citrullinated peptide in the biological sample obtained from said subject.Type: ApplicationFiled: June 20, 2016Publication date: October 18, 2018Applicant: Cedars-Sinai Medical CenterInventors: Jennifer VAN EYK, Justyna FERT-BOBER, Erin CROWGEY, Ronald HOLEWINSKI, Benjamin Phillip BERMAN
-
Publication number: 20180136220Abstract: Described herein are methods for identifying signature peptides for quantifying a polypeptide of interest in a sample. The methods include cleaving the polypeptide into peptides; detecting a multiplicity of the peptides with a quantitative analytical instrument; comparing the linearity of signals attributable to pairs of the peptides in a multiplicity of samples; and selecting signature peptides from a group of peptides with more highly correlated signals.Type: ApplicationFiled: May 31, 2016Publication date: May 17, 2018Applicants: Cedars-Sinai Medical Center, The John Hopkins UniversityInventors: Eric GROTE, Qin FU, Jennifer Van Eyk, Vidya VENKATRAMAN
-
Patent number: 9746481Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injuries. Brain injury can include overt or traumatic brain injury, as well as subclinical brain injury (SCI). In one embodiment, a method for diagnosing SCI in a patient comprises (a) collecting a sample from the patient; (b) measuring the levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises ASTN1, BAI3, CNDP1, ERMIN, GFAP, GRM3, KLH32, MAGE2, NRG3, NRGN, OMG, SLC39A12, RTN1, and MT3; and (c) comparing the levels of the panel of biomarkers with predefined levels of the same panel of biomarkers that correlate to a patient having SCI and predefined levels of the same panel of biomarkers that correlate to a patient not having SCI, wherein a correlation to one of the predefined levels provides the diagnosis.Type: GrantFiled: October 14, 2011Date of Patent: August 29, 2017Assignee: The Johns Hopkins UniversityInventors: Allen Dale Everett, James Francis Casella, Jennifer Van Eyk
-
Patent number: 9678086Abstract: The present invention relates to the field of Alzheimer's disease (AD). More specifically, the present invention provides methods and compositions useful in diagnosing and assessing AD. In another embodiment, a method for diagnosing Alzheimer's Disease (AD) in a patient comprises the steps of (a) obtaining CSF sample from the patient; (b) adding to the sample isotopically labeled peptides identical to a portion of one or more biomarker proteins, wherein the one or more biomarker proteins comprise total APP, APP isoform 751, APP isoform 770, amyloid beta 40 peptide, APOE, and Clusterin; and (c) measuring the one or more biomarker proteins in the sample using mass spectrometry, wherein the level of one or more biomarker proteins compared to a control correlates with AD in the patient.Type: GrantFiled: September 10, 2013Date of Patent: June 13, 2017Assignee: The Johns Hopkins UniversityInventors: Jennifer Van Eyk, Xiaogian Liu, Richard O'Brien
-
Publication number: 20150212098Abstract: The present invention relates to the field of Alzheimer's disease (AD). More specifically, the present invention provides methods and compositions useful in diagnosing and assessing AD. In another embodiment, a method for diagnosing Alzheimer's Disease (AD) in a patient comprises the steps of (a) obtaining CSF sample from the patient; (b) adding to the sample isotopically labeled peptides identical to a portion of one or more biomarker proteins, wherein the one or more biomarker proteins comprise total APP, APP isoform 751, APP isoform 770, amyloid beta 40 peptide, APOE, and Clusterin; and (c) measuring the one or more biomarker proteins in the sample using mass spectrometry, wherein the level of one or more biomarker proteins compared to a control correlates with AD in the patient.Type: ApplicationFiled: September 10, 2013Publication date: July 30, 2015Inventors: Jennifer Van Eyk, Xiaogian Liu, Richard O'Brien
-
Patent number: 9039994Abstract: This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention.Type: GrantFiled: July 29, 2013Date of Patent: May 26, 2015Assignee: The Johns Hopkins UniversityInventors: Jennifer Van Eyk, Simon Sheng, Qin Fu
-
Publication number: 20150051115Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injuries. Brain injury can include overt or traumatic brain injury, as well as subclinical brain injury (SCI). In one embodiment, a method for diagnosing SCI in a patient comprises (a) collecting a sample from the patient, (b) measuring the levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises ASTN1, BAI3, CNDP1, ERMIN, GFAP, GRM3, KLH32, MAGE2, NRG3, NRGN, OMG, SLC39A12, RTN1, and MT3; and (c) comparing the levels of the panel of biomarkers with predefined levels of the same panel of biomarkers than correlate to a patient having SCI and predefined levels of the same panel of biomarkers that correlate to a patient not having SCI, wherein a correlation to one of the predefined levels provides the diagnosis.Type: ApplicationFiled: October 27, 2014Publication date: February 19, 2015Inventors: Allen Dale Everett, James Francis Casella, Jennifer van Eyk
-
Publication number: 20140274765Abstract: The invention relates to secreted proteins from cardiac stem cells (cardiospheres and cardiosphere-derived cells) or myocytes for diagnostic and/or therapeutic useType: ApplicationFiled: December 19, 2013Publication date: September 18, 2014Applicant: The Johns Hopkins UniversityInventors: Eduardo Marban, Jennifer Van Eyk, Miroslava Stasna
-
Publication number: 20140186852Abstract: This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention.Type: ApplicationFiled: July 29, 2013Publication date: July 3, 2014Applicant: The Johns Hopkins UniversityInventors: Jennifer Van Eyk, Simon Sheng, Qin Fu
-
Publication number: 20140045713Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injuries. Brain injury can include overt or traumatic brain injury, as well as subclinical brain injury (SCI). In one embodiment, a method for diagnosing SCI in a patient comprises (a) collecting a sample from the patient; (b) measuring the levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises ASTN1, BAI3, CNDP1, ERMIN, GFAP, GRM3, KLH32, MAGE2, NRG3, NRGN, OMG, SLC39A12, RTN1, and MT3; and (c) comparing the levels of the panel of biomarkers with predefined levels of the same panel of biomarkers that correlate to a patient having SCI and predefined levels of the same panel of biomarkers that correlate to a patient not having SCI, wherein a correlation to one of the predefined levels provides the diagnosis.Type: ApplicationFiled: October 14, 2011Publication date: February 13, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Allan Dale Everett, James Francis Casella, Jennifer Van Eyk